Research programme: LADD immunotherapeutics - Aduro BioTech

Drug Profile

Research programme: LADD immunotherapeutics - Aduro BioTech

Alternative Names: Cancer vaccines - Aduro BioTech; Infectious disease vaccines - Aduro BioTech; KBMA Ba; KBMA vaccines; LADD vaccines; Lm Ft; Lm HBV; Lm HIV; Lm Malaria; Lm Melanoma; Lm Prostate

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cerus Corporation
  • Developer Aduro BioTech
  • Class Bacterial vaccines; Cancer vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Anthrax; Hepatitis B; HIV infections; Malaria; Malignant melanoma; Tularaemia

Most Recent Events

  • 05 Jan 2016 Aduro BioTech receives patent allowance for its LADD platform in USA
  • 10 Aug 2015 Aduro Biotech in collaboration with Janssen plan phase I trials for Lung cancer and Prostate cancer in USA
  • 16 Oct 2014 LADD product candidates licensed to Janssen Biotech worldwide for the treatment of Lung cancer and certain other cancers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top